Pharmact Group

Pharmact Group is a private European healthcare and biotechnology company centered on Pharmact Holding AG in Baar, Switzerland, with operating entities in Germany. The group is developing a patented biotechnologically engineered enzyme, D016, with its lead development project BELACT focused on arteriosclerosis/atherosclerosis and familial hypercholesterolemia. Company materials describe preclinical proof-of-concept, pre-toxicology work, regulatory consultation with BfArM/EMA, and preparation for GMP manufacturing, toxicology, and future clinical trial entry. Pharmact also positions the enzyme for broader medical, licensing, and cosmetic applications, and states that German subsidiaries handle product development, production, logistics, and distribution. Overall, the company appears to be an early-stage cardiovascular biotech built around a proprietary enzyme/IP platform rather than a diversified late-stage drug pipeline.